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    T h e  p u r p o s e  o f  t h e  p r e s e n t  s t u d y  w a s  t o  e v a l u a t e  t h e  
prokinetic effects of mosapride with non-invasive assessment 
of myoelectrical activity in the small intestine and caecum of 
healthy horses after jejunocaecostomy. Six horses underwent 
celiotomy  and  jejunocaecostomy,  and  were  treated  with 
mosapride (treated group) at 1.5 mg/kg per osos once daily 
for 5 days after surgery. The other six horses did not receive 
treatment and were used as controls (non-treated group). 
The electrointestinography (EIG) maximum amplitude was 
used  to  measure  intestinal  motility.  Motility  significantly 
decreased following surgery. In the treated group, the EIG 
maximum amplitude of the small intestine was significantly 
higher than in the controls from day 6∼31 after treatment. 
These findings clearly indicate that mosapride could overcome 
the decline of intestinal motility after jejunocaecostomy in 
normal horses.
Keywords: horse, ileus, mosapride, small intestine
Introduction
  Jejunocaecostomy is performed in horses if the distal ileum 
requires resection due to strangulating obstruction and/or 
stenosis or bypass [6-8]. However, after jejunocaecostomy, 
the horses experienced reduced intestinal motility with 
postoperative ileus, resulting in death [2,5,12]. From rodent 
studies, it is apparent that at least three major mechanisms 
are involved in manipulation-induced postoperative ileus 
(neurogenic, inflammatory, and pharmacologic) [1]. 
Medical treatment with prokinetic agents is known to be 
effective for gastrointestinal motility dysfunctions, such as 
postoperative ileus [3,14,15].
  Mosapride selectively acts on the 5-hydroxytryptamine 4 
(5HT4) receptor, thereby increasing neuronal release of 
acetylcholine in the digestive tract and promoting 
gastrointestinal motility in dogs [17,18]. Although it has 
been reported that mosapride promotes motility in the small 
intestine and caecum of horses [13], no study has investigated 
the effects of mosapride on reduced motility of the small 
intestine and caecum using electrointestonography (EIG) in 
horses after celiotomy and jejunocaecostomy. Therefore, 
the purpose of the present study was to evaluate the effects 
of mosapride on motility of the small intestine and caecum 
in horses after jejunocaecostomy using EIG.
Materials and Methods
Experimental animals
  Twelve healthy thoroughbred horses (5 stallions, 4 mares, 
and 3 geldings) were used in the present study. Six horses 
(5.0 ± 3.2 years old; 484 ± 32 kg) were treated with mosapride 
(treated group) after jejunocaecostomy, and the other six 
horses (6.8 ± 4.0 years old; 504 ± 41 kg) were used as 
controls (non-treated group). The horses were fed an ordinary 
two-meal diet per day (0.9 kg oats, 0.3 kg bran, and 3.5 kg 
dried grass per meal) with unrestricted water intake. Housing 
and care of the horses and conduct of the study were in 
accordance with a protocol approved by the Obihiro 
University Institutional Animal Care and Use Committee.
Surgical procedure 
  All foods and water were withheld for 12 h before the 
surgery. All horses were intravenously pre-medicated with 
4 μg/kg of medetomidine (Domitor; Orion, Japan), and 
anesthesia was intravenously induced 5 min later with 0.03 
mg/kg of diazepam (10 mg, Horizon; Yamanouchi 158    Kouichi Okamura et al.
Fig. 1. Electrointestinography (EIG) electrode position. A: Small
intestine, B: Ceacum, ●: EIG mini-amplifier, ○: EIG in different
electrodes.
Pharmaceutical, Japan) and 2.2 mg/kg of ketamine 
(Veterinary Ketalar 50; Sankyo Yell Yakuhin, Japan). 
Guaifenesin (25∼50 mg/kg; Kyoto Pharmaceutical 
Industries, Japan) was infused rapidly until the horse became 
ataxic. The trachea was then intubated and the horse was 
held on a surgical table. Anesthesia was maintained by 
inhalation of halothane and oxygen. At the beginning of 
surgery, 20 mg/kg of cefalotin sodium (Coaxin; Tobishi 
Pharmaceutical Industries, Japan) and 1.1 mg/kg of flunixin 
meglumine (Banamine; Dainippon Sumitomo Pharmaceutical, 
Japan) were administered to each horse intravenously.
    The surgical area was routinely prepared for aseptic 
surgery in dorsal recumbency and a ventral midline celiotomy 
was performed. The caecum was exteriorized and the apex 
was pulled caudally to expose the dorsal taenital band. The 
surgical method of jejunocaecostomy used in the present 
study was essentially the same as performing hand suturing 
as used by Donawick et al. [4]. The ileum and jejunum 
were resected approximately 50 and 200 cm proximal to 
the ileocaecal junction, respectively. 
  After the surgical intervention, 20 mg/kg of cefalotin 
sodium and 1.1 mg/kg of flunixin meglumine were 
intravenously administered twice a day at 9:00 and 18:00 
for 5 days, and 10,000 ml of lactated Ringer’s solution 
(Solulact; Terumo, Japan) was intravenously administered 
twice a day for 4 days. Incisions were treated as necessary. 
Water was offered ad libitum starting 13 h after the surgery, 
and the horses were fed 0.7 kg of alfalfa softened by hot 
water 47 h after operation. The quantity of feed was then 
gradually increased over a period of 5 days until the 
amount of their meal diet reached its former level.
Treatment with mosapride 
  Mosapride (Gasmotin; Dainippon Sumitomo Pharmaceutical, 
Japan) at a dose of 1.5 mg/kg was administered in 1,000 ml 
distilled water via a nasogastric tubation once daily at 9:00 
am for 5 consecutive days. 
Evaluation of intestinal motility
  EIGs of the small intestine and caecum were performed 
on conscious horses at rest in a stall. After clipping the hair 
over the paralumbar fossa on the left and right sides of the 
abdomen, the skin was washed and EIG electrodes were 
installed via surface electrodes (Vitrode M-150 Disposable 
Electrodes; Nihon Kohden, Japan) at three sites: the front 
edge of the tuber coxae (EIG mini-amplifier), the intersection 
of the horizontal line extending from the tuber coxae and 
the rear edge of the last rib (noninductive electrodes), and 
the apex of an inverted regular triangle formed by placing 
the other two electrodes on the other apexes (EIG mini- 
amplifier; Fig. 1). At a sampling rate of 1 Hz, the frequency 
was measured within the range of 1.6∼12 cycles per min. 
An electrogastrographic (EGG) recorder (Nipro EG; A&D, 
Japan) and a digitrapper EGG system were used to measure 
the percutaneous potential of the small intestine and caecum 
[10]. The system was attached to the trunk by means of a 
saddle, a girth, and a saddlecloth.
  Preoperative EIGs were recorded for 24 h before the 
surgical operation after horses were fed an ordinary diet. 
Postoperative EIG data were collected immediately 
following recovery from general anesthesia, continued to 
be recorded for 10 consecutive days, and were thereafter 
collected on days 17, 24, and 31 for 24 h each day. 
  For EIG analysis, a running spectrum method with fast 
Fourier transform was used. The waveform was divided 
into 1-min intervals. The relative value of maximum 
amplitude (μv) of the wave form at 10 min per h was 
calculated. Preoperative data were regarded as 100% of 
relative values. 
Statistical analysis
  Data were indicated as the mean ± SD. Two-way repeated 
measure ANOVA was used to determine significant 
differences between the treated group and the control. 
Significant differences were evaluated by a post-hoc test 
(Fisher’s PLSD). The significance level was set at p ＜ 
0.05.
Results
  In the control group, the EIG maximum amplitudes of the 
small intestine and caecum on postoperative day 1 were 
significantly lower than those recorded before the surgical 
operation (44.2 ± 19.1% vs. 100.0 ± 0.0% for the small 
intestine and 45.7 ± 19.3% vs. 100.0 ± 0.0% for the 
caecum, Figs. 2A and B). The EIG maximum amplitudes 
of the small intestine and caecum tended to increase from 
postoperative days 2∼10; however, they stayed significantly 
lower than those before the surgical operation (p ＜ 0.05). 
EIG maximum amplitudes from postoperative days 10∼31 
continued to increase reaching preoperative levels. 
  In mosapride-treated horses, the EIG maximum amplitudes 
of the small intestine were significantly higher than those 
in the control group from postoperative days 6∼31 (Fig. 
2A). Although the EIG maximum amplitudes of the 
caecum in mosapride-treated horses tended to be higher 
than those in the control group, the difference was not Effects of mosapride on motility of the small intestine and caecum in normal horses after jejunocaecostomy    159
Fig. 2. Electrointestinography maximum amplitude of the small intestine (A) and caecum (B). Preoperative value was taken as 100%
and each value was shown as mean ± SD, [○: treated group (N = 6), △: control (N = 6)]. 
a,bSignificant differences (p ＜ 0.05) compared
with each preoperative value of the treated group (A) and the control group (B). *,†Significant differences (p ＜ 0.05, p ＜ 0.01) compared
between the treated group and the control group on the same day.
statistically significant (Fig. 2B).
Discussion
  Mosapride selectively acts on 5-HT4 receptors and increases 
the level of acetylcholine released from cholinergic nerve 
endings in the digestive tract [17,18]. Acetylcholine binds to 
muscarinic receptors on the smooth muscle and induces 
contractions. Generally, mosapride is administrated three 
times a day in humans. However, it has been reported that 
administration of 1.5 mg/kg once a day significantly 
enhances small intestinal and caecal motility in horses 
[13]. Therefore, in the present study, mosapride was 
administered at 1.5 mg/kg once a day for 5 consecutive 
days. 
  In mosapride-treated horses, the parameters measured 
returned to their preoperative levels earlier compared to the 
control group. These findings indicate that mosapride 
effectively improves a decline in intestinal motility by 
increasing both peristalsis and the number of intestinal 
contractions [11]. In addition, the EIG maximum amplitudes 
from days 2∼31 were significantly higher in mosapride- 
treated horses than in the control group. It is considered 
that the EIG maximum amplitude reflects contractility of 
smooth muscle [9]. Therefore, it is believed that mosapride 
enhances contractile motility and thus alleviates decline in 
intestinal motility.
  In the caecum, no significant difference between the two 
groups was observed in the EIG maximum amplitude. 
Therefore, we conclude that mosapride acts more effectively 
on the small intestine than on the caecum in healthy horses. 
It has been reported that the distribution of 5HT4 receptor 
differs depending on gastrointestinal sites and species. In 
horses, it is known that 5HT4 receptors are widely 
distributed in the ileum and pelvic flexure [16]. Therefore, 
it is suggested that the difference in the distribution of the 
5HT4 receptor is at the base of different effects of 
mosapride in the small intestine and caecum.
    In this study, we demonstrated that administration of 
mosapride is an effective treatment for the decline of intestinal 
motility in the period following jejunocaecostomy in healthy 
horses. Mosapride appeared to have more of an effect on 
motility in the small intestine than in the caecum. It is 
therefore concluded that administration of mosapride may 
improve the decline of intestinal motility after surgery, but 
further studies are needed to understand the mechanism by 
which this drug may act as a prokinetic and to determine 
whether the potential beneficial effects on intestinal 
motility occur in clinical colic cases.
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